Posted on 05/02/2010 in Pharmaceutical Company Financials Takeda has revealed its latest financial results, which cover the first three quarters of the fiscal year ending March 31st 2010.
It revealed net sales for the period of 1,127,946 billion Japanese yen (8,002,324 pounds).
Consolidated operating income increased by 116.3 billion Japanese yen - or 48.5 per cent - to 356.2 billion Japanese yen, compared to 2009 figures.
Meanwhile, the company's consolidated net sales within its pharmaceuticals division amounted to 1,062.2 billion Japanese yen.
Throughout the period, Takeda worked to enhance its research and development operations, initiating a phase III clinical trial of hypertension treatment TAK-536 in June 2009 and phase II study of TAK-700, a therapy for advanced prostate cancer.
"Takeda intensively invests its management resources in its core therapeutic areas of lifestyle-related diseases - oncology and urological diseases, central nervous system diseases and gastroenterological diseases," the firm iterated.
In other Takeda news, the firm announced this week that Mepact (mifamurtide) - its treatment for osteosarcoma - has been made commercially available in the EU.Other news stories from 05/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
